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the Prevention of Nitrate Tolerance in Patients With Chronic
Heart Failure
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YASURO SUGISHITA, MD, FACC‡
Mitsukaido, Ami, and Tsukuba, Ibaraki, Japan
Objectives. This study was designed to evaluate the effect of
carvedilol on nitrate tolerance in patients with chronic heart
failure.
Background. The attenuation of cyclic guanosine 5*-
monophosphate (cGMP) production due to inactivation of guan-
ylate cyclase by increased superoxide has been reported as a
mechanism of nitrate tolerance. Carvedilol has been known to
combine alpha/beta-blockade with antioxidant properties.
Methods. To evaluate the effect of carvedilol on nitrate toler-
ance, 40 patients with chronic heart failure were randomized to
four groups that received either carvedilol (2.5 mg once a day
[carvedilol group, n 5 10]), metoprolol (30 mg once a day
[metoprolol group, n 5 10]), doxazosin (0.5 mg once a day
[doxazosin group, n 5 10]) or placebo (placebo group, n 5 10).
Vasodilatory response to nitroglycerin (NTG) was assessed with
forearm plethysmography by measuring the change in forearm
blood flow (FBF) before and 5 min after sublingual administra-
tion of 0.3 mg NTG, and at the same time blood samples were
taken from veins on the opposite side to measure platelet cGMP.
Plethysmography and blood sampling were obtained serially at
baseline (day 0); 3 days after carvedilol, metoprolol, doxazosin or
placebo administration (day 3); and 3 days after application of a
10-mg/24-h NTG tape concomitantly with carvedilol, metoprolol,
doxazosin or placebo (day 6).
Results. There was no significant difference in the response of
FBF (%FBF) and cGMP (%cGMP) to sublingual NTG on day 0
and day 3 among the four groups. On day 6, %FBF and %cGMP
were significantly lower in the metoprolol, doxazosin and placebo
groups than on day 0 and day 3, but these parameters in the
carvedilol group were maintained.
Conclusions. These results indicated that carvedilol may pre-
vent nitrate tolerance in patients with chronic heart failure during
continuous therapy with NTG.
(J Am Coll Cardiol 1998;32:1194–200)
©1998 by the American College of Cardiology
Organic nitrates are widely used in cardiovascular medicine, but
their continuous administration can result in the rapid develop-
ment of tolerance (1–3). The underlying mechanisms responsible
for nitrate tolerance probably are multifactorial (4) and may
include neurohormonal counterregulatory mechanisms (5), intra-
vascular volume expansion (6) or intrinsic abnormalities such as
desensitization of the target enzyme guanylate cyclase (7) or a
decrease in nitroglycerin (NTG) biotransformation (8). Recent
experimental data have demonstrated that nitrate tolerance is
associated with increased vascular superoxide anion production
(9). Therefore, antioxidant may be effective in the prevention of
the development of nitrate tolerance. An increase in oxidative
stress, due to an increase in free radicals, a relative deficiency in
the endogenous antioxidant reserve or both, has been suggested
to be one of the contributing factors in the pathogenesis of heart
failure (10), and carvedilol has been reported to have a beneficial
effect on the survival of patients with heart failure (11–13).
Carvedilol has been known to combine alpha/beta-blockade with
antioxidant properties (14–17). Therefore, this study was de-
signed to investigate the effect of carvedilol on nitrate tolerance
during continuous administration of NTG in patients with chronic
heart failure. Moreover, to clarify the mechanism of preventive
effects of carvedilol on nitrate tolerance, we compared these
effects among carvedilol (alpha/beta-blocker with antioxidant),
metoprolol (beta-blocker without antioxidant), doxazosin (alpha-
blocker without antioxidant) and placebo.
Methods
Patient population. The study population comprised 40 pa-
tients with chronic heart failure ranging in age from 45 to 69
years. Heart failure was defined as dyspnea or fatigue on exertion
for $3 months, in association with a left ventricular ejection
fraction #0.45 as assessed by echocardiography, and a maximum
load ,7 metabolic equivalents as assessed by a treadmill exercise
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test. The clinical status and background medications received by
each patient were stable for $2 months before enrollment in this
study. Patients were excluded from participation if they had
primary valvular disease, active myocarditis or any condition
other than heart failure that could limit exercise (e.g., hepatic,
renal or endocrine disease). Patients receiving calcium channel
blocking agents, alpha- or beta-adrenergic agonist or antagonist
drugs, specific antiarrhythmic drugs or antioxidants (vitamin E,
vitamin C or hydralazine) were also excluded. All medications
were withdrawn .48 h before the study. Patients’ characteristics
are shown in Table 1.
Study protocol. We measured the vasodilator response to
sublingual NTG by plethysmography and platelet cyclic
guanosine 59-monophosphate (cGMP) at baseline (day 0),
after 3 days of administration of carvedilol (Artist; Daiichi
Seiyaku, Tokyo, Japan), metoprolol SR (Lopresor; Novartis,
Tokyo, Japan), doxazosin (Cardenalin; Pfizer, Tokyo, Japan)
or placebo (day 3), and 3 days after the application of a
10-mg/24-h NTG tape concomitantly with carvedilol, metopro-
lol, doxazosin or placebo (day 6). An 18-gauge heparin lock
was inserted in the contralateral forearm to allow venous blood
sampling for measurements of the platelet cGMP level.
The baseline forearm blood flow (FBF) was recorded by
plethysmography before and 5 min after administration of 0.3 mg
of sublingual NTG on day 0. Subjects were then allocated by a
double-blind parallel design to four groups that received either
2.5 mg carvedilol once a day (carvedilol group, n 5 10), 30 mg
metoprolol SR once a day (metoprolol group, n 5 10), 0.5 mg
doxazosin once a day (doxazosin group, n 5 10), or placebo once
a day (placebo group, n 5 10). Subjects returned 3 days after
treatment with carvedilol, metoprolol, doxazosin or placebo for
measurements of the FBF and the platelet cGMP before and
after administration of sublingual NTG. A 5-mg NTG tape
(Millisrol Tape; Nippon Kayaku, Tokyo, Japan) was then applied
twice a day. Final measurements were obtained 3 days after
treatment with combined continuous transdermal NTG. The
study protocol is shown in Figure 1.
The study protocol was approved by the ethics committee of
KINU Medical Association Hospital, Mitsukaido, Japan, and
the University of Tsukuba, Tsukuba, Japan, and written in-
formed consent for participation in this study was obtained
from all subjects.
Assessment of the vasodilator response to NTG. To eval-
uate the vasodilator response to NTG, the FBF was measured
with a mercury-in-silastic strain gauge plethysmograph and the
venous occlusion technique. The strain gauge was placed 5 cm
below the antecubital crease and connected to a calibrated
plethysmograph. The FBF is expressed as the rate of change in
the forearm volume (ml/min/100 ml forearm). The pressure in
Abbreviations and Acronyms
cGMP 5 cyclic guanosine 59-monophosphate
FBF 5 forearm blood flow
NTG 5 nitroglycerin
Figure 1. Study protocol.
Table 1. Patient Characteristics
Carvedilol
(n 5 10)
Metoprolol
(n 5 10)
Doxazosin
(n 5 10)
Placebo
(n 5 10)
Age (yr) 59 6 8 57 6 7 58 6 9 56 6 9
Male/female 7/3 6/4 6/4 7/3
New York Heart Association
functional class (II/III/IV)
8/2/0 8/2/0 7/3/0 8/2/0
Cause of heart failure
Coronary artery disease 6 5 7 6
Nonischemic dilated cardiomyopathy 4 5 3 4
Left ventricular ejection fraction 0.37 6 0.09 0.38 6 0.09 0.35 6 0.07 0.38 6 0.08
Heart rate (beats/min) 83 6 10 85 6 10 84 6 12 85 6 12
Systolic pressure (mm Hg) 122 6 15 125 6 17 123 6 14 127 6 15
Diastolic pressure (mm Hg) 72 6 12 77 6 13 75 6 11 76 6 12
Patients receiving digitalis 2 2 1 2
Patients receiving diuretics 9 8 9 8
Patients receiving angiotensin-
converting enzyme inhibitor
8 8 7 8
Patients receiving vasodilator 4 4 3 3
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the venous occlusion or congesting cuff was 40 mm Hg.
Circulation to the hand was arrested during determinations of
FBF by inflation of a cuff around the wrist to suprasystolic
pressure. We used the average of three measurements made at
15-s intervals to represent the FBF. The intraobserver and
interobserver variabilities for repeated measurements are
0.12 6 0.31 and 0.04 6 0.10 ml/min/100 ml forearm in our
laboratory.
Preparation of platelet cGMP. Blood samples were drawn
into syringes containing 5 mM ethylenediaminetetraacetic acid
and a cGMP phosphodiesterase inhibitor (1023 mol/L 2-O-
propoxyphenyl-8-azapurin-6-one dissolved in 1% triethanol-
amine). Platelet-rich plasma and platelet-poor plasma were
prepared immediately after blood sampling by centrifugation
at 200 g for 20 min. Platelet-rich plasma was further centri-
fuged at 2,500 g for 10 min, and the supernatant was discarded.
The pellet was suspended in modified Tyrode’s solution (con-
taining 0.35% bovine serum albumin and 5 mM Hepes, pH
7.35) to obtain a final platelet count of 2 to 3 3 106 platelets/ml.
The samples were stored frozen at 270° C until analysis (18).
Platelet cGMP assay. Trichloroacetic acid (0.5 ml in a final
concentration of 6%) was added to 1 ml of the platelet
preparation. After centrifugation at 2,500 g for 20 min, trichlo-
roacetic acid was extracted four times from the supernatant
with water-saturated ether. The aqueous phase was then
assayed for cGMP using a commercially available radioimmu-
noassay kit (Yamasa Shoyu, Choshi, Japan) (19). The results
are expressed in picomoles/109 platelets. The coefficients of
variation averaged 3.4% for intraassay error and 11.9% for
interassay error.
Statistical analysis. Results are expressed as the mean 6
SD for the FBF and the platelet cGMP level. Differences
among the test days or differences before and after sublingual
NTG were analyzed by repeated measures analysis of variance
(ANOVA) with Bonferroni’s test, and differences among
groups were analyzed by factorial analysis of variance followed
by Scheffe´ F test. Values of p , 0.05 were considered
significant.
Results
Heart rate and blood pressure (Table 2). Heart rate did
not change during this study in the four groups. There was no
difference in heart rate before and after sublingual NTG or
among days 0, 3 and 6 in the four groups. Mean blood pressure
was significantly decreased after sublingual NTG on days 0 and
3 in the four groups. However, in the metoprolol, doxazosin
and placebo groups, mean blood pressure after sublingual
NTG was not decreased on day 6. On the other hand, in the
carvedilol group the change of mean blood pressure after
sublingual NTG on day 6 was similar to that on day 0.
FBF (Table 3). The FBF increased after sublingual NTG
on days 0 and 3 in the four groups. There was no significant
difference in the FBF before and after NTG among the four
groups. On day 6 the FBF increased in the metoprolol,
doxazosin and placebo groups after sublingual NTG, but was
significantly lower compared with days 0 and 3. In the carve-
dilol group the change in the FBF after sublingual NTG was
similar to those on days 0 and 3. The NTG after sublingual
NTG on day 6 was significantly greater in the carvedilol group
than in the other groups.
There was no significant difference in the percent increase
in the FBF on days 0 and 3 among the four groups (day 0:
carvedilol group, 32 6 11%; metoprolol group, 33 6 11%;
doxazosin group, 32 6 12%; placebo group, 30 6 11%; day 3:
carvedilol group, 33 6 10%; metoprolol group, 33 6 11%;
doxazosin group, 32 6 10%; placebo group, 29 6 10%). The
percent increase in the metoprolol, doxazosin and placebo
groups was significantly lower on day 6 (metoprolol group,
12 6 4%; doxazosin group, 12 6 5%; placebo group, 13 6 4%)
than on days 0 and 3. In the carvedilol group the percent
increase in the FBF after sublingual NTG was maintained on
day 6 (31 6 9%) and was significantly greater than in the other
groups (Fig. 2).
Platelet cGMP level (Table 3). The platelet cGMP level
was significantly increased after sublingual NTG in the four
groups on days 0 and 3. There was no significant difference
among the four groups on days 0 and 3.
The platelet cGMP level before and after sublingual NTG
on day 6 was significantly lower in the metoprolol, doxazosin
and placebo groups than that on days 0 and 3, whereas the
platelet cGMP level in the carvedilol group on day 6 was
significantly increased after sublingual NTG, and was signifi-
cantly higher than in the other groups. There was no significant
difference in the platelet cGMP level in the carvedilol group
among test days.
There was no difference in the percent increase in the platelet
cGMP level between the carvedilol group and the placebo group
on days 0 and 3 (day 0: carvedilol group, 38 6 10%; metoprolol
group, 40 6 11%; doxazosin group, 41 6 11%; placebo group,
39 6 12%; day 3: carvedilol group, 39 6 11%; metoprolol group,
40 6 12%; doxazosin group, 40 6 11%; placebo group, 39 6
10%). The percent increase in cGMP level in the metoprolol,
Figure 2. Percentage of increase in the forearm blood flow after
sublingual nitroglycerin. Data are expressed as the mean value 6 SD.
*p , 0.05 versus days 0 and 3; †p , 0.05 versus carvedilol group.
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doxazosin and placebo groups was significantly lower on day 6
(metoprolol group, 11 6 6%; doxazosin group, 12 6 5%; placebo
group, 14 6 5%) compared with days 0 and 3. The percent
increase in the platelet cGMP level in the carvedilol group was
maintained on day 6 (36 6 9%) and was significantly greater than
in the other groups (Fig. 3).
Discussion
This placebo-controlled, double-blind study demonstrated
that carvedilol maintained the response of vasodilation and the
intracellular production of cGMP after sublingual NTG during
transdermal application of NTG. These findings suggest that
carvedilol, an alpha/beta-blocker with antioxidant properties, may
prevent nitrate tolerance in patients with chronic heart failure.
Proposed mechanisms of nitrate tolerance. Although the
phenomenon of nitrate tolerance was first described during the
early part of this century (20), it was not considered clinically
important (21) until later research demonstrated that nitrate
tolerance limited the efficacy of these drugs in patients with
ischemic heart disease and congestive heart failure (22–24).
The mechanism of nitrate tolerance is multifactorial (4,23,25).
Nitrate tolerance is thought to be due to the inability of the
vascular tissue to respond to NTG (26). Previous studies have
proposed four possible mechanisms of nitrate tolerance after
chronic exposure: (1) desensitization of the target enzyme
guanylate cyclase (7); (2) an increase in phosphodiesterase
activity (27); (3) intracellular sulfhydryl group depletion (28);
and (4) impaired NTG biotransformation (29). Moreover,
Mu¨nzel et al. (9) recently demonstrated that enhanced angio-
tensin II activities resulted in increased production of oxygen-
derived radicals, which inhibit the dilator action of NTG-
derived nitric oxide.
The effect of antioxidants on nitrate tolerance. An increase
in oxidative stress due to an increase in free radicals may be
one of the contributing factors in the mechanisms of nitrate
tolerance. These radicals inactivate the enzymes involved in
the release of nitric oxide from NTG, leading to impaired
cGMP production. Therefore, we thought that some antioxi-
dants may prevent nitrate tolerance. However, there are some
investigations that evaluated the effect of antioxidant on
nitrate tolerance. In an experimental animal study, Bassenge
and Fink (30) demonstrated that vitamin C prevented nitrate
tolerance in the dilatation of the coronary artery and the
production of platelet cGMP. Recently two studies demon-
strated the preventive effect of hydralazine on nitrate tolerance
(31,32). Mu¨nzel et al. (33) proposed that antioxidant proper-
ties may contribute to the preventive effect of hydralazine on
nitrate tolerance. We also reported that oral supplementation
of vitamins E and C could prevent nitrate tolerance in FBF and
platelet cGMP in normal volunteers and patients with ischemic
heart disease (34,35), and that intravenous application of
vitamin C could prevent nitrate tolerance in patients with
congestive heart failure (36).
The effect of carvedilol on nitrate tolerance. Carvedilol, in
addition to being an alpha/beta-adrenergic antagonist and aTa
bl
e
2.
H
ea
rt
R
at
e
an
d
M
ea
n
Bl
oo
d
Pr
es
su
re
Be
fo
re
an
d
A
fte
r
Su
bl
in
gu
al
A
dm
in
ist
ra
tio
n
of
N
itr
og
ly
ce
rin
D
ay
0
D
ay
3
D
ay
6
C
ar
ve
di
lo
l
G
ro
up
M
et
op
ro
lo
l
G
ro
up
D
ox
az
os
in
G
ro
up
Pl
ac
eb
o
G
ro
up
C
ar
ve
di
lo
l
G
ro
up
M
et
op
ro
lo
l
G
ro
up
D
ox
az
os
in
G
ro
up
Pl
ac
eb
o
G
ro
up
C
ar
ve
di
lo
l
G
ro
up
M
et
op
ro
lo
l
G
ro
up
D
ox
az
os
in
G
ro
up
Pl
ac
eb
o
G
ro
up
H
ea
rt
ra
te
(b
ea
ts
/m
in
)
Be
fo
re
81
6
11
81
6
10
82
6
11
82
6
10
80
6
10
78
6
11
81
6
12
82
6
11
81
6
11
79
6
12
80
6
12
82
6
13
A
fte
r
85
6
11
85
6
11
86
6
10
85
6
12
81
6
11
77
6
12
81
6
13
88
6
13
82
6
10
80
6
11
81
6
11
83
6
11
Bl
oo
d
pr
es
su
re
(m
m
H
g)
Be
fo
re
91
6
12
93
6
11
91
6
12
92
6
12
89
6
10
88
6
12
90
6
11
92
6
11
88
6
12
89
6
10
88
6
10
90
6
10
A
fte
r
86
6
11
*
86
6
10
*
85
6
11
*
86
6
11
*
84
6
11
*
85
6
11
*
85
6
12
*
86
6
12
*
84
6
12
*
87
6
11
86
6
11
89
6
12
D
at
a
ar
e
ex
pr
es
se
d
as
m
ea
n
6
SD
.B
ef
or
e
5
be
fo
re
su
bl
in
gu
al
ad
m
in
ist
ra
tio
n
of
ni
tr
og
ly
ce
rin
;a
fte
r
5
af
te
r
su
bl
in
gu
al
ad
m
in
ist
ra
tio
n
of
ni
tr
og
ly
ce
rin
.*
p
,
0.
05
ve
rs
us
be
fo
re
.
1197JACC Vol. 32, No. 5 WATANABE ET AL.
November 1, 1998:1194–200 CARVEDILOL ON NITRATE TOLERANCE
vasodilator, appears to be an antioxidant and free radical
scavenger as well (14–17). In this study carvedilol prevented
the attenuation in the vasodilatory response and the intracel-
lular production of cGMP after administration of sublingual
NTG during continuous transdermal application of NTG. To
clarify the mechanism of the preventive effect of carvedilol on
nitrate tolerance, we compared these effects with metoprolol, a
beta-blocker without antioxidant, and doxazosin, an alpha-
blocker without antioxidant. In our results metoprolol and
doxazosin did not prevent nitrate tolerance. Therefore, we
speculated that antioxidant properties of carvedilol might
contribute to the preventive effect on nitrate tolerance. Carve-
dilol is approximately tenfold more potent as an antioxidant
than vitamin E. Several metabolites of carvedilol (most notably
SB-209995) are extremely potent antioxidants, being 30 to 80
times more potent than carvedilol as antioxidants and up to
1,000 times more potent than vitamin E (17,37). Moreover, the
potency of carvedilol as an antioxidant was recently shown to
be less than 100 pM in a rat cardiac ischemia/reperfusion
model in vitro (38). To our knowledge, this study provides the
first evidence in the clinical investigation that the development
of nitrate tolerance may be prevented by supplementing with a
small dose of carvedilol.
Study limitations. There are some limitations in this study.
First, we measured the platelet cGMP level to evaluate the
intracellular production of cGMP. The in vivo effects of NTG
on the intracellular production of cGMP in the vascular
smooth muscle cells can be evaluated only in biopsy specimens.
Nitroglycerin activates soluble guanylate cyclase in platelets,
and the increased level of platelet cGMP inhibits platelet
adhesion (39,40). Platelets contain predominantly the soluble
guanylate cyclase (41,42). Therefore, platelets are an appro-
priate material for the clinical measurement of intracellular
cGMP. In a previous study we demonstrated that the platelet
cGMP level can be used as an indicator of the effects of NTG
and the development of nitrate tolerance (18).
Figure 3. Percentage of increase in the platelet cyclic guanosine
59-monophosphate level after sublingual nitroglycerin. Data are ex-
pressed as the mean value 6 SD. *p , 0.05 versus days 0 and 3; †p ,
0.05 versus carvedilol group.
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Second, we evaluated the effect of a single small dosage of
carvedilol (2.5 mg/day), metoprolol (30 mg/day) and doxazosin
(0.5 mg/day). The doses of carvedilol and metoprolol used in
this study are starting doses in the therapy of heart failure in
Japan. Of course the dosage in this study was lower than that
in other carvedilol studies on heart failure, and we did not
observe any changes in heart rate and blood pressure before
sublingual NTG among three testing days (days 0, 3 and 6) in
this study. It is important to note that our results indicate that
antioxidant properties of carvedilol may be effective even in
small doses, which cannot provide any effects as an alpha/beta-
blockade. So carvedilol may be a useful antioxidant in small
doses to prevent nitrate tolerance in patients with chronic
heart failure.
Third, we studied the effects of carvedilol only in patients
with chronic heart failure, but did not study normal subjects. It
is well known that patients with chronic heart failure are
characterized by systemic vasoconstriction and a reduced
peripheral perfusion due to endothelial dysfunction of periph-
eral resistance arteries (43). In our previous study FBF and
platelet cGMP before sublingual NTG were 2.6 6 0.7 ml/min/
100 ml forearm (mean 6 SD) and 0.62 6 0.05 pmol/109
platelets (mean 6 SEM) in normal volunteers (36). Our results
of FBF and platelet cGMP in this study were lower than those
in our previous study. These differences between the normal state
and the heart failure state may be associated with baseline
endothelial-dependent vasodilation (endothelial dysfunction in
the heart failure state). However, the percent increase in FBF and
platelet cGMP after sublingual NTG in this study were similar to
those in our previous study. These results indicate that there is no
difference in the effects of NTG (endothelial-independent vaso-
dilation) in the normal state and the heart failure state.
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